细胞因子抑制剂在新型冠状病毒感染中的治疗进展  

Advances in the treatment of cytokine inhibitors in COVID-19

作　　者：霍凯凯 和平[1] 杨拴盈[1] Huo Kaikai;He Ping;Yang Shuanying(Department of Respiratory and Critical Care Medicine,the Second Affiliated Hospital of Xi′an Jiaotong University,Xi′an 710000,China)

机构地区：[1]西安交通大学第二附属医院呼吸与危重症医学科,西安710000

出　　处：《国际呼吸杂志》2023年第5期521-526,共6页International Journal of Respiration

基　　金：陕西省重点研发计划(2020GXLH-Y-010)。

摘　　要：严重急性呼吸系统综合征冠状病毒2型(SARS-CoV-2)导致了新型冠状病毒感染(COVID-19)大流行。免疫炎症反应失调在COVID-19的发生发展中发挥重要作用。在重型和危重型患者中, 细胞因子风暴是免疫反应失调的关键组成部分。过度释放的促炎细胞因子会造成组织损伤, 使机体发生高热、弥漫性血管内凝血、休克、多器官衰竭、甚至死亡。使用细胞因子抑制剂可有效缓解重型和危重型COVID-19患者的细胞因子风暴, 从而起到改善临床症状并防止病情加重恶化的作用。本文旨在阐述细胞因子抑制剂治疗COVID-19患者的研究进展。The infection of severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)causes the Coronavirus Disease 2019(COVID-19)pandemic.Dysregulation of immune inflammatory response plays an important role in the development of COVID-19.Cytokine storm is considered as a key component of the dysregulated immune response in severe and critically ill patients with COVID-19.Excessively released proinflammatory cytokines result in tissue damage,leading to hyperthermia,diffuse intravascular coagulation,shock,multiple organ failure,and even death.Cytokine inhibitors can effectively alleviate cytokine storm in severe and critically ill patients with COVID-19,thereby improving clinical symptoms and preventing disease exacerbation and deterioration.This review aims to summarize the advances of cytokine inhibitors in the treatment of severe and critically ill patients with COVID-19.

关 键 词：新型冠状病毒感染 新型冠状病毒 糖皮质激素类 细胞因子抑制剂 IL-6受体拮抗剂 

分 类 号：R563.1[医药卫生—呼吸系统]